We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Biogen Inc | NASDAQ:BIIB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.76 | 1.28% | 217.58 | 205.00 | 220.00 | 218.66 | 214.70 | 215.56 | 916,376 | 01:00:00 |
From May 2021 to May 2024
By Matt Grossman
Biogen Inc. and Samsung Bioepis Co. Ltd. have received a positive opinion from Europe's Committee for Medicinal Products for Human Use for Byooviz, a biosimilar candidate to treat eye conditions, the companies said Friday.
Byooviz references an existing drug called Lucentis, which is used to treat retinal vascular disorders, which can cause blindness. Byooviz was developed by Samsung Bioepis and would be commercialized by Biogen if the drug receives final European Commission approval.
The committee's positive opinion was based on a Phase 3 study in which the drug demonstrated equivalence in efficacy for both primary endpoints.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
June 25, 2021 08:30 ET (12:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Biogen Chart |
1 Month Biogen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
